Anti‐PD‐1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who
have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and …

Abstract Programmed death‐1 (PD1) blockade is an efficient and safe therapeutic option in
patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, a …

Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%–20%
of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) …

Introduction Achieving a PET-negative metabolic (m) CR with salvage chemotherapy prior to
autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin lymphoma (R/R …

Introduction Long-term efficacy of anti-PD1 therapy and the need for a consolidation with
allogenic haematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients …

The efficacy and safety of low‐dose anti‐PD1 antibodies in relapsed/refractory classical
Hodgkin lymphoma (cHL) require confirmation. Pembrolizumab (100 mg every 3 weeks …

Autologous stem cell transplantation (ASCT) can be curative for patients with
relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 …

This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo)
as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma …

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has
improved considerably in recent years owing to the approval of highly active novel agents …

Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable
for stem cell transplant (SCT) and have a poor prognosis. This phase IV study …